When Charles Kummeth joined Bio-Techne in 2013, the purified protein development company was experiencing a downturn. He was tasked with rejuvenating it, and so far, under his leadership, the company has more than doubled revenue. Externally, it’s made 15 acquisitions in five years, with an eye to getting involved in the complete workflow of cell and gene therapies, from reagent development to diagnostics and treatment efforts to investing $45 million into a new protein manufacturing facility. Kummeth’s job now is to get new offerings to market with Medicare approval and to continue making acquisitions to achieve Bio-Techne’s goals, while facing challenges such as the trade war with China.